These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 32862320)

  • 1. Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
    Uprety D; Halfdanarson TR; Molina JR; Leventakos K
    Curr Treat Options Oncol; 2020 Aug; 21(11):86. PubMed ID: 32862320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung.
    Wolin EM
    Chest; 2017 May; 151(5):1141-1146. PubMed ID: 27373769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
    Caplin ME; Baudin E; Ferolla P; Filosso P; Garcia-Yuste M; Lim E; Oberg K; Pelosi G; Perren A; Rossi RE; Travis WD;
    Ann Oncol; 2015 Aug; 26(8):1604-20. PubMed ID: 25646366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.
    Naraev BG; Ramirez RA; Kendi AT; Halfdanarson TR
    Clin Lung Cancer; 2019 May; 20(3):e376-e392. PubMed ID: 30910575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
    Dasari A; Bergsland EK; Benson AB; Cai B; Huynh L; Totev T; Shea J; Duh MS; Neary MP; Dagohoy CG; Shih BE; Maurer VE; Chan J; Kulke MH
    Oncologist; 2019 Aug; 24(8):1066-1075. PubMed ID: 30610008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Carcinoid tumors].
    Pregun I; Bodoky G; Rácz K; Tulassay Z
    Orv Hetil; 2010 Nov; 151(46):1885-94. PubMed ID: 21044939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K
    Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug therapy for neuroendocrine tumours].
    Tóth M
    Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving landscape of neuroendocrine tumors.
    Bergsland EK
    Semin Oncol; 2013 Feb; 40(1):4-22. PubMed ID: 23391109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and therapeutic advances in neuroendocrine tumours.
    Caplin ME; Ratnayake GM
    Nat Rev Endocrinol; 2021 Feb; 17(2):81-82. PubMed ID: 33335329
    [No Abstract]   [Full Text] [Related]  

  • 12. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
    Cives M; Soares HP; Strosberg J
    Curr Opin Oncol; 2016 Jul; 28(4):359-66. PubMed ID: 27138571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radionuclide Therapy for Neuroendocrine Tumors.
    Cives M; Strosberg J
    Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
    Pivonello C; Rousaki P; Negri M; Sarnataro M; Napolitano M; Marino FZ; Patalano R; De Martino MC; Sciammarella C; Faggiano A; Rocco G; Franco R; Kaltsas GA; Colao A; Pivonello R
    Endocrine; 2017 Jun; 56(3):603-620. PubMed ID: 27688013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations.
    Wolin EM
    Oncologist; 2015 Oct; 20(10):1123-31. PubMed ID: 26306904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.
    Yordanova A; Ahrens H; Feldmann G; Brossart P; Gaertner FC; Fottner C; Weber MM; Ahmadzadehfar H; Schreckenberger M; Miederer M; Essler M
    Clin Nucl Med; 2019 May; 44(5):e329-e335. PubMed ID: 30932975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoid tumors outside the abdomen.
    Koehler K; Iams WT
    Cancer Med; 2023 Apr; 12(7):7893-7903. PubMed ID: 36560885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
    Lo Russo G; Pusceddu S; Prinzi N; Imbimbo M; Proto C; Signorelli D; Vitali M; Ganzinelli M; Maccauro M; Buzzoni R; Seregni E; de Braud F; Garassino MC
    Tumour Biol; 2016 Oct; 37(10):12991-13003. PubMed ID: 27460087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.